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Mononuclear cells from peripheral blood of thalassemic patients
were treated with morpholino oligonucleotides antisense to ab-
errant splice sites in mutant b-globin precursor mRNAs (pre-
mRNAs). The oligonucleotides restored correct splicing and trans-
lation of b-globin mRNA, increasing the hemoglobin (Hb) A syn-
thesis in erythroid cells from patients with IVS2–654ybE, IVS2–745y
IVS2–745, and IVS2–745yIVS2–1 genotypes. The maximal Hb A level
for repaired IVS2–745 mutation was '30% of normal; Hb A was still
detectable 9 days after a single treatment with oligonucleotide.
Thus, expression of defective b-globin genes was repaired and
significant level of Hb A was restored in a cell population that
would be targeted in clinical applications of this approach.
One of the most common genetic diseases of mankind isb-thalassemia. It affects large populations in the Mediter-
ranean basin, Middle East, South East Asia, and Africa. Ap-
proximately 80 million people are carriers of the thalassemia
trait and the percentage of carriers worldwide is increasing.
Concomitant increases in the number of patients, presently
numbering several hundred thousands, are held down by high
infant mortality in underdeveloped countries, by population
screening, genetic counseling, and abortions; the growing need
for clinical treatment is evident (1).
The disease is due to mutations causing defective b-globin
gene expression and deficiency of b-globin and adult hemoglobin
(Hb) A. Homozygotes or compound heterozygotes for severe
defects are affected with thalassemia major or Cooley’s anemia,
lethal if untreated, and suffer pronounced anemia, bone defor-
mities, and hepatomegaly and splenomegaly (2). Regular, life-
long transfusions combined with iron chelation constitute cur-
rent treatment. Bone marrow transplantation, the only cure, is
limited by the scarcity of suitable donors and facilities. Exper-
imental protocols to stimulate synthesis of fetal hemoglobin by
sodium butyrate or hydroxyurea (3–6) or b-globin gene repair or
replacement (4, 7, 8) have not yet been fully tested at the clinical
level. Clearly there is a need for alternative treatments to replace
the costly and cumbersome transfusion regimen.
More than 100 thalassemic mutations causing defective b-glo-
bin gene expression and b-globin deficiency have been identi-
fied, but the ones causing aberrant splicing are among the most
common (9). They are found in intron 1 (IVS1–5, IVS1–6, and
IVS1–110) and intron 2 (IVS2–654, IVS2–705, and IVS2–745)
of the b-globin gene (9–15). A mutation in codon 26 of the gene
also results in activation of an aberrant splicing pathway and a
mutated b-globin protein (bE) (16, 17). A common pathogenic
feature of these mutations is activation of aberrant splice sites
and modification of the splicing pathways, even though the
correct splice sites remain potentially functional.
Aberrant splicing of several of the b-globin splicing mutants
has been shown in cell free extracts (18), in transfected HeLa
based cell lines (19–22), and in a transgenic mouse model (23).
More importantly, in vitro and in transfected cell lines correct
splicing was restored by blocking the aberrant splice sites with
antisense oligonucleotides. Here we report that treatment of
erythroid progenitors from peripheral blood of thalassemic
patients carrying the IVS2–654 and 2745 mutations with oli-
gonucleotides antisense to aberrant splice sites in b-globin
pre-mRNA efficiently restored correct splicing and production
of significant amounts of Hb A. These results indicate that the
oligonucleotides entered the erythroid progenitor cells, mi-
grated to the nucleus, hybridized to the aberrant splice sites, and
led to the formation of spliceosomes and subsequent splicing at
the correct splice sites. In consequence, expression of a defective
b-globin gene was repaired in a cell population that would
constitute the target in clinical applications of this approach.
Materials and Methods
Mononuclear Cells. Blood samples were from two Italian patients
with b-thalassemia major, IVS2–745yIVS2–745 and IVS2–745y
IVS2–1, and from a Thai patient with thalassemia intermedia,
IVS2–654ybE. As controls, blood from an Italian subject het-
erozygous for the IVS2–745 mutation and from a normal subject
also were used. Informed consent was obtained in accordance
with Italian and Thai regulations.
Following the manufacturer’s protocols, total mononuclear
cells were isolated by Ficoll gradient (lymphocyte separation
medium, ICNyCappel, Aurora, OH), purified from the remain-
ing red blood cells with ammonium chloride solution (StemCell,
Vancouver, BC, Canada), and washed twice with Iscove’s mod-
ified Dulbecco’s medium, 2% fetal bovine serum. The cells were
suspended at 2 3 106 cells per ml in the above medium, 30% fetal
bovine serum, 1% BSA (the latter two from StemCell, Vancou-
ver, BC.), 1024 M 2-mercaptoethanol, 2 mM L-glutamine, 100
unitsyml penicillin-streptomycin, 3 unitsyml of recombinant
human Epoetin a (Amgen, Thousand Oaks, CA), and 25 ngyml
recombinant mouse stem cell factor (R & D Systems, Minne-
apolis, MN), and incubated in 5% CO2 at 37°C. The above fresh
medium (300 ml) containing double concentrations of Epoetin a
and stem cell factor were added per milliliter on days 4 and 8 of
culture; the same amount of old medium was subsequently
replaced with 23 Epoetin a and 23 stem cell factor medium
every 4 days.
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To detect erythroid forming unit (CFU-E) and burst-forming
unit erythroid (BFU-E) colonies in the mononuclear cell cul-
tures the cells were plated at 2 3 105 cells per ml of methylcel-
lulose containing culture medium (Stem Cell, Vancouver, BC).
Hemoglobinized CFU-E and BFU-E colonies appeared at 8–18
days of culture.
Oligonucleotide Treatment. The 18- or 25-mer morpholino oligo-
nucleotides targeted to the 39-cryptic splice site (39-18,
CAUUAUUGCCCUGAAAG, 39-25, GTATCATTATTGC-
CCTGAAAGAAAG) and 18- or 25-mer morpholino oligonu-
cleotides targeted to the aberrant 59-splice sites in the IVS2–654
(654–18, GCUAUUACCUUAACCCAG, 654–25,TTGCTAT-
TACCTTAACCCAGAAATT) or in the IVS2–745 mutants
(745–25, CAGAATGGTACCTGGATTGTAGGTG) were
used in the experiment. A morpholino oligonucleotide targeted
to the a-globin gene (25 mer, CCCGCCGCTCACCTT-
GAAGTTGACC) was used as a negative control. Morpholino
oligonucleotides (24) were prepared and purified at GeneTools
(Corvallis, OR) and AVI Biopharma (Portland, OR).
Cellular delivery of the oligonucleotides was performed by
passing 2 3 106 cells suspended at 37°C in 200 ml of culture media
containing the desired concentration of morpholino oligonucle-
otide seven times through a syringe with a 25-gauge needle. After
1 h of incubation at 37°C, 800 ml of medium was added and
incubation was continued at 37°C for the times indicated in the
figure legends. Syringe loading of suspension cells was the
equivalent of scrape loading for adherent cells (25) and allowed
for penetration of concentrated oligonucleotides into the cells.
Isolation and Analysis of b-Globin mRNA. The total cellular RNA
was isolated with TRI-Reagent (Molecular Research Center,
Cincinnati, OH) and (50–200 ng) analyzed by reverse transcrip-
tion (RT)-PCR by using rTth DNA polymerase (Perkin–Elmer,
Norwalk, CT) with 0.2 mCi of [a-32P]dATP per sample at up to
25 cycles. Assay of b-globin pre-mRNA was performed with
forward and reverse primers spanning positions 21–43 of exon 2
(Fig. 1, primer b) and positions 119–142 of intron 2 (primer c)
in b-globin pre-mRNA, respectively. Aberrant and correct splic-
ing of human IVS2–745 b-globin pre-mRNA was detected with
forward primer b and the reverse primer spanning positions 6–28
of exon 3 (primer d). Correction of human b-globin IVS2–654
pre-mRNA splicing in the compound heterozygote IVS2–
654ybE was detected by using a forward allele-specific bA primer
a (GCAAGGTGAACGTGGATGAAGTTGGTGTTG, posi-
tions 50–79 of b-globin exon 1) and the reverse primer d. The
RT-PCR products were separated on a 7.5% nondenaturing
polyacrylamide gel and detected by autoradiography. No prod-
uct was detectable without the reverse transcription step.
Immunoblot Analysis of the Hemoglobins. For hemoglobin analysis
by cellulose acetate electrophoresis, 1.5 3 106 of the cultured
mononuclear cells were washed twice with PBS, suspended in 20
ml of hemolysate reagent, and centrifuged at 14,000 rpm to
remove the cell membranes. Approximately 3 ml of the super-
natant was applied on Titan III-H cellulose acetate strips (76 3
60 mm) alongside with standard hemoglobins. Electrophoresis
was performed with Supre-Heme buffer, pH 8.2 at 350 V for
35 min. The electrophoresis protocol and the materials were
from Helena Laboratories (Beaumont, TX). Protein bands were
visualized by staining the cellulose acetate strip with 0.5%
Ponceau S and destaining with 5% acetic acid. Subsequently, the
strip was blocked for 1 h in 5% solution of fat-free dry milk in
PBS containing 0.1% Tween 20 and incubated with polyclonal
affinity-purified chicken anti-human hemoglobin IgG as primary
antibody and rabbit anti-chicken horseradish peroxidase-
conjugated IgG as secondary antibody, both at 1,000-fold dilu-
tion in the blocking solution (Accurate, Westbury, NY). The
blots were developed with an ECL detection system (Amersham,
Piscataway, NJ).
Cytoimmunofluorescence. The cultured cells were washed twice
with PBS and loaded at 105 cells per well of printed microscope
slides (Carlson Scientific, Peotone, IL). After air drying, the cells
were fixed for 10 min in 1:1 methanol:acetone at 220°C. The
slides were hydrated in PBS and incubated with mouse anti-
human Hb A b8–12 mAb (Accurate, Westbury, NY), at 120
mgyml for 1 h and with a secondary antibody, FITC anti-mouse
donkey IgG1 diluted 200-fold for 1 h (Jackson ImmunoResearch
Laboratories, West Grove, PA). Purified mouse IgG1 (Sigma,
Saint Louis, MO) at 120 mgyml served as the nonimmune
control.
All autoradiograms were scanned using Adobe PHOTOSHOP
and figures were generated with Adobe ILLUSTRATOR. NIH
IMAGE 1.61 software was used for quantitation.
Results
Experimental Approach. A C to T mutation at nucleotide 654
(IVS2–654) and a C to G mutation at nucleotide 745 (IVS2–745)
of b-globin intron 2 create aberrant 59-splice sites at positions
652 and 745, respectively. These splice sites and a common
Fig. 1. Correction of splicing of thalassemic human b-globin pre-mRNA by
antisense oligonucleotides. Boxes, exons; solid lines, introns; dashed lines,
correct and aberrant splicing pathways; the aberrant 59-splice sites created by
IVS2–654 and IVS2–745 mutations and the cryptic 39-splice site activated
upstream are indicated; heavy bars, oligonucleotide antisense to 39- or 59-
splice sites; arrows, primers used in the RT-PCR reaction. The length (in
nucleotides) of the appropriate RT-PCR products generated on aberrantly and
correctly spliced mRNAs (ab and c mRNA, respectively) are indicated below
each diagram.
Fig. 2. Time course of pre-mRNA and mRNA b-globin expression in cultured
mononuclear cells from normal human blood assayed by RT-PCR of total RNA.
(Upper) Expression of b-globin pre-mRNA; (Lower) expression of b-globin
mRNA (see Materials and Methods). The numbers on the left indicate the size,
in nucleotides, of the pre-mRNA and the correctly spliced b-globin mRNA.
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cryptic 39-splice site at nucleotide 579 are recognized by the
splicing machinery, leading to inclusion of a fragment of the
intron into the spliced mRNAs. The retained intron sequences
generate a stop codon that prevents proper translation of the
mRNA and causes a deficiency in b-globin and resultant
b-thalassemia (10, 14) (Fig. 1). b-Globin pre-mRNA splicing in
normal individuals and in thalassemic patients occurs in mono-
nuclear erythroid progenitor and precursor cells and ceases
when the cells mature to enucleated reticulocytes.
To determine the optimal conditions for antisense oligonu-
cleotide treatments, a culture of mononuclear cells isolated from
peripheral blood of a healthy volunteer was established, and the
time course of b-globin pre-mRNA and mRNA expression was
assayed by RT-PCR (see Materials and Methods). The initial lack
of detectable levels of both these RNAs (Fig. 2, days 0–2)
suggested that committed erythroid progenitors were absent in
the cell preparation and that the pre-mRNA and spliced mRNA
that appeared subsequently (Fig. 2) must have originated from
a small number of stem cells or early progenitors present in the
blood sample. These results indicated that the culture conditions
allowed erythropoietic differentiation and transcription and
processing of b-globin pre-mRNA, the target for antisense
oligonucleotides. Erythroid differentiation was confirmed by the
fact that hemoglobinized colonies appeared in cultures in meth-
ylcellulose containing medium (not shown). Note that the steady
state level of b-globin mRNA is higher than that of its pre-
mRNA, hence the detection of mRNA prior (Fig. 2, day 4) to
pre-mRNA (Fig. 2, day 6).
Restoration of Correct Splicing of IVS2–654 b-Globin pre-mRNA. On
day 14 of culture, when a high level of b-globin pre-mRNA was
expected (Fig. 2, days 13–15), the mononuclear cells from a
thalassemic patient carrying the IVS2–654ybE mutations were
treated with morpholino oligomers (24, 25) complementary to
aberrant splice sites activated in IVS2–654 b-globin pre-mRNA.
Morpholino analogs of oligonucleotides were selected because
they are resistant to nucleases, do not allow degradation of RNA
in the RNA-oligonucleotide hybrids by RNase H, and bind to
targeted splice sites forming duplexes of high Tm (22).
Consistent with the b0 phenotype of IVS2–654 thalassemia
(9), RT-PCR (primers a and d, Fig. 1) of total RNA from
untreated cells (Fig. 3A, lane 1) detected only aberrantly spliced
IVS2–654 b-globin mRNA and no correct b-globin mRNA.
Primer a is specific for wild type b-globin, and therefore bE
mRNA present in the sample (data not shown) was not detected.
The 24-h treatment of the cells with 18- or 25-mer oligonucle-
otides targeted either to the cryptic 39-splice site (39218 and
225, Fig. 3A, lanes 3–6) or the IVS2–654 59-splice site (654–18
and 225, Fig. 3A, lanes 7–10) showed dose-dependent correction
of aberrant splicing. The correction of b-globin splicing required
a high concentration of the oligonucleotides, 45 mM, but was
quite efficient in cultures treated with either 654–18 or 654–25
oligomers. Treatments with 39-18 and 225 mers were less
effective due to lower susceptibility of the cryptic 39-splice site
to the oligonucleotides (21).
The experiments illustrated in Fig. 3B show linearity and
reproducibility of the RT-PCR protocol used. The amount of the
PCR product was proportional to the amount of input RNA as
were the relative amounts of PCR products generated from
aberrantly and correctly spliced RNA (26). No product was
detectable without the reverse transcription step (not shown).
Quantitative analysis of the ratio of correctyaberrant RNAs
showed that, at its best, repair of splicing yielded 35–50% of
correct b-globin mRNA (Fig. 3, lanes 8 and 10). Control
oligomers had no effect (Fig. 3, lanes 2 and 11), confirming the
sequence specificity of correction; none of the oligomers showed
any obvious cytotoxicity (not shown).
Hemoglobin A Synthesis in Oligonucleotide-Repaired IVS2–654ybE
Erythroid Cells. To test for hemoglobin synthesis, lysates of
oligomer-treated cells separated by electrophoresis on cellulose
Fig. 3. (A) Restoration of correct splicing of IVS2–654 b-globin pre-mRNA by
antisense morpholino oligomers in cultured mononuclear cells from periph-
eral blood of IVS2–654ybE thalassemic patient (YC). RT-PCR analysis of total
cellular RNA. On day 14 of culture, the cells were treated for 24 h with
morpholino oligomers indicated at the top of the figure. Lanes 1, 2, and 11:
control cells, untransfected, transfected with 745–25 mer, and with an a-glo-
bin-25mer, respectively. Note lack of production of correct b-globin mRNA.
Lanes 3–6: cells transfected with oligonucleotides targeted to the 39 cryptic
splice site (39218 mer and -25 mer) at two different concentrations (15 and 45
mM). Lanes 7–10: cells transfected with oligonucleotides targeted to the
aberrant 59-splice site (654–18 mer and 225 mer), at 15 and 45 mM, each. Lane
12, b-globin mRNA from normal human blood. Due to the presence of
correctly spliced mRNA derived from the bE gene (codon 26G3A), a 59 bA
codon 26 allele-specific forward primer was used (see Materials and Methods).
The numbers on the left indicate the size, in nucleotides, of RT-PCR products
representing the aberrantly (367) and correctly (294) spliced b-globin mRNAs.
Unless otherwise noted similar designations are used in subsequent figures.
(B) Linearity of RT-PCR assay. Increasing amounts (indicated on the Left panel)
of total RNA from HeLa cells stably expressing correctly spliced b-globin mRNA
were subjected to RT-PCR (20 cycles) and the products were analyzed and
quantitated as described in Materials and Methods. Aberrantly spliced IVS2–
654 RNA and correctly spliced b-globin RNA from HeLa cell lines were mixed
in ratios indicated on the Right panel and analyzed as above. The results were
averaged from three independent experiments.
Fig. 4. Immunoblot of hemolysate of mononuclear cells from patient YC
probed with anti-human hemoglobin antibody. Concentrations of 654–18
mer antisense oligonucleotide are indicated above the lanes. Lanes 1–2,
hemolysate from cells transfected on day 8 and harvested on day 11; lanes 3–6,
hemolysate from cells transfected on day 10 and harvested on day 13 (lanes 3
and 4) and 15 (lanes 5 and 6); lane 7, hemoglobin standards (S); and lane 8,
hemolysate of red blood cells from an IVS2–745 heterozygote subject (H).











acetate were probed with polyclonal anti-hemoglobin antibody
(see Materials and Methods and Fig. 4). In untreated 8- and
10-day cultures of mononuclear cells (Fig. 4, lanes 1, 3, and 5),
the only detectable species of hemoglobin were Hb E and Hb F.
In a sample treated at day 8 and cultured for additional 3 days
(lane 2), Hb A became detectable. The level of Hb A increased
significantly upon treatment at day 10 (lane 4) and persisted for
5 days posttreatment (lane 6). Interestingly, in treated cultures
the levels of Hb F decreased (see lanes 3 vs. 4 or 5 vs. 6),
suggesting that restoration of expression of Hb A suppressed Hb
F formation in repaired erythroid progenitor cells (lanes 2, 4, 6).
However, the possibility that oligonucleotide treatment might
have resulted in unspecific changes in g-chain synthesis cannot
be ruled out.
Repair of Splicing and Hemoglobin A Synthesis in IVS2–745 Erythroid
Cells. A similar series of experiments was carried out with
mononuclear cells from two patients with IVS2–745yIVS2–745
and IVS2–745yIVS2–1 thalassemias. In a 7-day culture from the
homozygous patient, DD, aberrantly spliced mRNA (band of 396
nucleotides) and small amounts of correct b-globin mRNA
(band 231) were detected in untreated cells or cells treated with
the control oligomer (Fig. 5A, lanes 1 and 2, respectively).
Treatment with morpholino oligomers targeted to the aberrant
splice sites showed a dose-dependent restoration of correct
b-globin splicing (Fig. 5A, lanes 3–8). In all samples, high levels
of newly generated b-globin mRNA, exceeding those of aberrant
RNA, were detected. This result suggests that, due to greater
stability of correct b-globin mRNA, its steady state level is higher
than that of its aberrant 745 counterpart. Even more efficient
production of correct b-globin mRNA was accomplished by
oligonucleotide treatment of 14 day cultures (Fig. 5B).
Similarly to patient DD, high levels of correct b-globin mRNA
also were generated by oligonucleotide treatment of cells from
the compound heterozygous patient, ZA (IVS2–745yIVS2–1),
after 7 and 14 days of culture (Fig. 5 C and D, band of 231
nucleotides). However, additional products generated by RT-
PCR differed in the two patients. Aberrantly spliced IVS2–745
mRNA was not detectable in ZA and, instead, a 278-nt product
became apparent. This band is caused by the cryptic splice site
activated by the IVS2–1 mutation, 47 nucleotides into intron 2
(27). Furthermore, as especially obvious in a 14-day culture (Fig.
5D), increased production of correct b-globin mRNA led to a
concomitant decrease in the intensity of the 278-nt band (Fig.
5D, lanes 3–8). The reasons for the latter result are not entirely
clear because it seems unlikely, although not impossible, that
transcription and processing of the IVS2–1 allele affected or was
affected by the expression of the IVS2–745 allele.
For analysis of oligonucleotide-induced hemoglobin produc-
tion in cells from IVS2–745 patients, the cultures at day 8 and 12
were treated with 45 mM 745–25 morpholino oligomer and
incubated for an additional 3 days. Analysis of protein lysates
from these cultures showed significant levels of the Hb A in both
IVS2–745 patients (Fig. 6). As in the IVS2–654 case, the
expression of Hb A repressed the levels of Hb F.
The extent of correction of Hb A synthesis by the oligonucle-
otide was estimated by comparison of the Hb A level in the
treated cells to that in 15-day cultured mononuclear cells from
an IVS2–745 carrier (Fig. 6, lane 9). The ratios of hemoglobin
A bands to Hb A2 bands (used as internal lane loading control)
in lanes 8 and 9 of Fig. 6 showed that the amount of Hb A in the
Fig. 5. Correction of splicing of b-globin pre-mRNA in mononuclear cells
from IVS2–745 homozygote (DD) and IVS2–745yIVS2–1 heterozygote (ZA)
thalassemic patients. On days 7 (A) and 14 (B) of the of culture, the cells from
patient DD were treated for 24 h with morpholino oligomers indicated above
the lanes. N, RNA from normal blood (lanes 9 and 5 in A and B, respectively).
Oligonucleotide targeted to the IVS2–654 aberrant 59-splice site, uninvolved
in splicing of IVS2–745 pre-mRNA served as negative control (lane 2 in A and
B). (C and D) Analogous treatments of 7- and 14-day cell cultures, respectively,
from patient ZA. a, Oligonucleotide targeted to human a-globin gene as
negative control (D, lane 9).
Fig. 6. Immunoblot of hemolysate of cultured mononuclear cells from
patient DD (lanes 1–4) and ZA (lanes 5–8) probed with anti-human hemoglo-
bin antibody. The concentration of the 745–25 mer antisense oligonucleotide
is indicated above the lanes. Lanes: 1–2 and 5–6, hemolysates from cells
transfected on day 8 and harvested on day 11; lanes 3–4 and 7–8, hemolysates
from cells transfected on day 12 and harvested on day 15; lane 9, hemolysate
of mononuclear cells from an IVS2–745 heterozygote subject harvested on day
15 of culture (H); and lane 10, hemoglobin standards (S).
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oligonucleotide-treated cells from patient ZA (lane 8) was
'30% of that in the carrier (lane 9).
Time Course of b-Globin mRNA and Hb A Repair. The persistence of
Hb A expression after a single treatment with 45 mM 745–25
morpholino oligomer was tested. The cells treated at day 8 of
culture exhibited a high level of b-globin mRNA 24 h after
treatment (Fig. 7, lower panel, lane 6) whereas Hb A appeared
2 days later, at day 11 (Fig. 7 Upper, lane 7). This result indicated
that after the oligonucleotide treatment the cells were unharmed
and that the expected course of erythroid differentiation con-
tinued. Furthermore, high levels of both Hb A and b-globin
mRNA persisted even after 9 days, i.e., at day 17 of cell culture.
Because the half-life of wild-type b-globin mRNA is between 30
and 50 h (28), its presence at day 17 suggested that the
morpholino oligomers persisted intracellularly at a sufficient
concentration to effect correction of splicing.
Detection of Hemoglobin A by Cytoimmunofluorescence in Erythroid
Cells from IVS2–745 Patients. To asses the expression of Hb A at
the cellular level, cells from IVS2–745 patients were immuno-
stained with anti-human b-globin mAb followed by anti-mouse
FITC-conjugated secondary antibody. The crossreactivity of
anti-human b-globin mAb with Hb E precluded this analysis in
the IVS2–654ybE material. Clear cytoplasmic hemoglobin stain-
ing in a large number of nucleated cells was easily detectable in
the material from both DD and ZA patients (Fig. 8, panels 6 and
8, respectively). The staining is specific for human Hb A because
cells not treated with the oligonucleotide (Fig. 8, panel 2) or
oligonucleotide-treated cells probed with nonimmune mouse
IgG1 (Fig. 8, panel 4) were negative.
Discussion
We have shown restoration of Hb A synthesis in erythroid
progenitor cells isolated from peripheral blood of thalassemic
patients by their treatment with morpholino oligomers targeted
to the aberrant splice sites in mutant b-globin pre-mRNAs. The
restoration was accomplished for b-thalassemias with three
different genotypes: IVS2–654ybE, IVS2–745yIVS2–745, and
IVS2–745yIVS2–1 and in two or three separate blood samples
from each patient. A single treatment with morpholino oli-
gomers of cells cultured for 8 days restored correct b-globin
mRNA, which persisted for additional 9 days (Fig. 7, lower panel,
lanes 6–10). Three days post-treatment the nucleated erythroid
cells became hemoglobinized, indicating translation of the newly
generated b-globin mRNA and formation of Hb A and suggest-
ing that under appropriate conditions the repaired cells may
progress into mature erythrocytes. Because the lifespan of the
latter is '120 days, the effects of the oligonucleotide treatment
could be quite prolonged. If similar results were accomplished in
patients with IVS2–654 and IVS2–745 thalassemias, their clin-
ical status could improve.
The morpholino analogs of oligonucleotides have numerous
desirable characteristics as modifiers of splice site selection and
in model systems performed better than the oligonucleotides
with other backbones (22). However, their free uptake into the
erythropoietic cells was limited and even syringe loading of the
cells, which entails mechanical disturbance of the cell membrane
(see Materials and Methods), required high concentrations of the
compounds. Note, however, that among close to 200 possible
modifications of oligonucleotides (29) only a few have been
tested in vivo and in clinical trials (30, 31). Furthermore, even
oligonucleotides poorly taken up by the cells may be efficiently
delivered by carriers such as cationic lipids or dendrimers (32).
Thus, although delivery as well as in vivo bioavailability and
pharmacodynamics of antisense oligonucleotides constitute se-
Fig. 7. Time course of restoration of correct splicing and Hb A synthesis in
mononuclear cells from patient ZA. Mononuclear cells on day 8 of culture were
transfected with 45 mM 745–25 mer antisense oligonucleotide and incubated
for 1–9 subsequent days with no additional oligonucleotide. Number of days
after oligonucleotide treatment is indicated at the top (Upper); other desig-
nations as in Fig. 3 and 5. Lanes: 6–10, oligonucleotide-treated cells, lanes 1–5,
no oligonucleotide controls. (Upper) Immunoblot of hemolysate of mononu-
clear cells probed with anti-human hemoglobin antibody. (Lower) Corre-
sponding RT-PCR assay.
Fig. 8. Cytoimmunofluorescent staining of Hb A in oligonucleotide-treated
cells from patients DD (panels 1–6) and ZA (panels 7–8). Cells were treated
with 45 mM 745–25 mer antisense oligonucleotide on day 12 of culture and
incubated for additional 3 days. Panels 1, 3, 5, and 7, phase contrast; panels 2,
4, 6, and 8, fluorescence. Panels 1 and 2, no oligonucleotide controls incubated
with anti-human b-globin mAb; panels 3 and 4, oligonucleotide-treated cells
incubated with nonimmune mouse IgG1; and panels 5–8, oligonucleotide-
treated cells incubated with anti-human b-globin mAb.











rious impediments to their successful clinical application, they do
not seem insurmountable. Importantly, the results reported here
indicate that when the antisense compounds targeted to the
aberrant splice sites are delivered to human erythroid progen-
itors, the targets for antisense therapy, these cells will respond as
expected leading to significant restoration of hemoglobin pro-
duction. Experiments on in vivo delivery of oligonucleotides in
a mouse model of IVS2–654 thalassemia (23) are in progress
(H.S., unpublished data).
The correction of splicing by morpholino oligomers was
dose-dependent and sequence-specific for both IVS2–654 and
IVS2–745 thalassemias but IVS2–745 pre-mRNA splicing was
corrected more efficiently than that of IVS2–654 pre-mRNA.
These results are consistent with our previous studies in model
cell culture systems (21) and suggest that the sensitivities of the
targeted splice sites in the IVS2–654 and IVS2–745 pre-mRNAs
differ. The differences most likely reflect the nature of the
interactions of the spliceosomes with the pre-mRNAs, which, in
turn, must be responsible for the b0 and b1 status of IVS2–654
and IVS2–745 thalassemias (10, 14), respectively.
IVS2–654, IVS2–745 and a rare mutant, IVS2–705 (15), all
activate the same 39-cryptic splice site. Similarly, a common
cryptic splice site is activated in Hb E, IVS1–5, and IVS1–6
thalassemias (14, 16, 17). An oligonucleotide targeted to a
branch point in intron 1 of the b-globin gene was found effective
in cell-free extracts in correction of splicing of pre-mRNA from
a common thalassemic mutation, IVS2–110 (18). Thus, only
three oligonucleotides may be needed in treatment of most of
splicing mutations in thalassemia. Nevertheless, this approach is
not applicable to b-thalassemias with other genotypes and is
limited in comparison to gene therapy, which may replace or
supplant any mutant with a correct gene. However, antisense
approach has several advantages. Antisense oligonucleotides
correct splicing of pre-mRNA that is properly transcribed from
the b-globin gene in its natural chromosomal environment and
controlled by the native locus control region. This precludes the
possibility of over- or inappropriate expression of b-globin
mRNA, an important consideration in treatment of hemoglo-
binopathies. Second, the approach offers a pharmacological
treatment, easier to implement than gene therapy. Third, the
treatment may be easily stopped if any undesirable effects are
observed. Note that modification of splicing by antisense oligo-
nucleotides is also applicable to other genetic disorders (33, 34)
and to diseases, such as certain cancers that may respond to
alteration of alternative splicing (ref. 35 and D. Mercatante and
R.K., unpublished data).
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